These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24002581)

  • 1. Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma.
    Wang H; Feng Y; Bao Z; Jiang C; Yan W; Wang Y; Zhang C; Liu Y; Zhang Q; Zhang W; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2089-96. PubMed ID: 24002581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion.
    Wang H; Wang Y; Bao Z; Zhang C; Liu Y; Cai J; Jiang C
    Oncol Rep; 2015 Sep; 34(3):1503-9. PubMed ID: 26165699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAMKK2, Regulated by Promoter Methylation, is a Prognostic Marker in Diffuse Gliomas.
    Liu DM; Wang HJ; Han B; Meng XQ; Chen MH; Yang DB; Sun Y; Li YL; Jiang CL
    CNS Neurosci Ther; 2016 Jun; 22(6):518-24. PubMed ID: 27012733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
    Bao Z; Feng Y; Wang H; Zhang C; Sun L; Yan Z; Liu Q; Guo T; Li M; Yang X; Jiang C; Zhang Q; Jiang T
    Oncol Rep; 2014 Jul; 32(1):250-60. PubMed ID: 24842301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F10 gene hypomethylation, a putative biomarker for glioma prognosis.
    Liu X; Tang H; Wang Z; Huang C; Zhang Z; She X; Wu M; Li G
    J Neurooncol; 2012 May; 107(3):479-85. PubMed ID: 22160665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
    Schliesser MG; Claus R; Hielscher T; Grimm C; Weichenhan D; Blaes J; Wiestler B; Hau P; Schramm J; Sahm F; Weiß EK; Weiler M; Baer C; Schmidt-Graf F; Schackert G; Westphal M; Hertenstein A; Roth P; Galldiks N; Hartmann C; Pietsch T; Felsberg J; Reifenberger G; Sabel MC; Winkler F; von Deimling A; Meisner C; Vajkoczy P; Platten M; Weller M; Plass C; Wick W
    Oncotarget; 2016 Dec; 7(50):82028-82045. PubMed ID: 27880937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis.
    Liu X; Tang H; Zhang Z; Li W; Wang Z; Zheng Y; Wu M; Li G
    Brain Res; 2011 May; 1391():125-31. PubMed ID: 21439273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coiled-coil domain containing 109B is a HIF1α-regulated gene critical for progression of human gliomas.
    Xu R; Han M; Xu Y; Zhang X; Zhang C; Zhang D; Ji J; Wei Y; Wang S; Huang B; Chen A; Zhang Q; Li W; Sun T; Wang F; Li X; Wang J
    J Transl Med; 2017 Jul; 15(1):165. PubMed ID: 28754121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic and epigenetic markers of gliomas].
    Semenova EV; Filatov MV
    Tsitologiia; 2013; 55(5):290-9. PubMed ID: 24592735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma.
    Dong X; Deng Q; Nie X; Zhang M; Jia W; Chen C; Xu C; Xu R
    Exp Mol Pathol; 2015 Apr; 98(2):192-9. PubMed ID: 25617528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of Dok7 expression mediated by DNMT1 promotes glioma cells proliferation.
    Hua CD; Bian EB; Chen EF; Yang ZH; Tang F; Wang HL; Zhao B
    Biomed Pharmacother; 2018 Oct; 106():678-685. PubMed ID: 29990858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aberrant expression of sox2 gene in malignant gliomas].
    Volnitskiĭ AV; Semenova EV; Shtam TA; Kovalev RA; Filatov MV
    Tsitologiia; 2014; 56(7):504-10. PubMed ID: 25696994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic neural epigenetic signature in high-grade glioma.
    Drexler R; Khatri R; Sauvigny T; Mohme M; Maire CL; Ryba A; Zghaibeh Y; Dührsen L; Salviano-Silva A; Lamszus K; Westphal M; Gempt J; Wefers AK; Neumann JE; Bode H; Hausmann F; Huber TB; Bonn S; Jütten K; Delev D; Weber KJ; Harter PN; Onken J; Vajkoczy P; Capper D; Wiestler B; Weller M; Snijder B; Buck A; Weiss T; Göller PC; Sahm F; Menstel JA; Zimmer DN; Keough MB; Ni L; Monje M; Silverbush D; Hovestadt V; Suvà ML; Krishna S; Hervey-Jumper SL; Schüller U; Heiland DH; Hänzelmann S; Ricklefs FL
    Nat Med; 2024 Jun; 30(6):1622-1635. PubMed ID: 38760585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    Wu X; Wu F; Xu D; Zhang T
    J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
    Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD
    Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
    Waha A; Felsberg J; Hartmann W; von dem Knesebeck A; Mikeska T; Joos S; Wolter M; Koch A; Yan PS; Endl E; Wiestler OD; Reifenberger G; Pietsch T; Waha A
    Cancer Res; 2010 Feb; 70(4):1689-99. PubMed ID: 20124482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.